"Frank joins us today to spearhead the EpiFix™ launch and lead the Sales & Marketing of our wound care initiative. We have EpiFix™ inventory, and MiMedx expects EpiFix™ to generate revenues in the second quarter. Our wound care initiative, serving both civilian and military, will focus on wound care clinics, hospitals, general practice clinics, physicians and private label opportunities," Petit said.
Bill Taylor, President and COO, stated, "With the substantial size of the market opportunity and the industry-leading amniotic tissue processing capabilities within our Surgical Biologics subsidiary, we believe that MiMedx has the potential to capture market share in multiple segments of this extremely large market. These segments include diabetic foot ulcers, bed sores, anti-scaring barriers, burn therapy, plastic surgery and several other clinical applications."
About the Company
MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company has an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focus
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved